How a gene affects weight-loss treatment response
Part of Hormones & metabolism clinical trials.
This study looks at how a weight-loss medication affects people with obesity who may have a specific gene difference (caveolin-1). It aims to understand why some people respond differently to GLP-1 treatments like semaglutide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your BMI is 30 or higher (or 27 or higher with conditions like high blood pressure or sleep apnea)
- You do not have diabetes
- You have not taken a GLP-1 drug (like Ozempic or Wegovy) in the last 6 months
- You have no history of pancreatitis or gallbladder stones
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your genes affect your body's response to a diabetes medication called semaglutide. It may help people with slightly high blood sugar (pre-diabetes) understand why some respond better than others.
This study tests whether switching to an oral weight-loss medication can help you keep off the weight you lost after stopping a GLP-1 injection like semaglutide or tirzepatide. You might qualify if you live in Massachusetts, are between 18 and 80, have a BMI of 30 or higher, lost at least 10% of your body weight on these injections, and are willing to be randomly assigned to a new treatment.
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
This trial looks at whether your genes can predict how well you will respond to weight loss medications like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro). It may help doctors choose the right drug for you based on your DNA.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study looks at how genetics may affect your body’s early response to oral semaglutide, a weight-related diabetes medicine. You may be considered if you are overweight (or overweight with prediabetes) and can safely take part in the research.
Hear when a new Overweight and Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.